Key genes and drug delivery systems to improve the efficiency of chemotherapy

Abstract

Cancer cells can develop resistance to anticancer drugs, thereby becoming tolerant to treatment through different mechanisms. The biological mechanisms leading to the generation of anticancer treatment resistance include alterations in transmembrane proteins, DNA damage and repair mechanisms, alterations in target molecules, and genetic responses, among others. The most common anti-cancer drugs reported to develop resistance to cancer cells include cisplatin, doxorubicin, paclitaxel, and fluorouracil. These anticancer drugs have different mechanisms of action, and specific cancer types can be affected by different genes. The development of drug resistance is a cellular response which uses differential gene expression, to enable adaptation and survival of the cell to diverse threatening environmental agents. In this review, we briefly look at the key regulatory genes, their expression, as well as the responses and regulation of cancer cells when exposed to anticancer drugs, along with the incorporation of alternative nanocarriers as treatments to overcome anticancer drug resistance.

Keywords

Cancer resistance / drug delivery systems / resistance genes

References

[1] Wang X,Chen X.Drug resistance and combating drug resistance in cancer..Cancer Drug Resist2019;2:141-60

[2] Liu FS.Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review..Taiwan J Obstet Gynecol2009;48:239-44

[3] Haider T,Vyas SP.Molecular determinants as therapeutic targets in cancer chemotherapy: An update..Pharmacol Ther2019;200:85-109

[4] Mills CC,Sampson VB.Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy..Cancer Res2018;78:320-5 PMCID:PMC5771851

[5] Gelbert LM,Lin X.Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine..Invest New Drugs2014;32:825-37 PMCID:PMC4169866

[6] Bukowski K,Kontek R.Mechanisms of Multidrug Resistance in Cancer Chemotherapy..Int J Mol Sci2020;21:3233 PMCID:PMC7247559

[7] Chorawala M,Shah G.Mechanisms of anticancer drugs resistance: an overview..Int J Pharm Sci Drug Res2012;4:1-9

[8] Zhou J,Chen L.The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents..Front Pharmacol2020;11:343 PMCID:PMC7100275

[9] Singh RK,Prasad DN.Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives..Eur J Med Chem2018;151:401-33

[10] Myers AL,Champlin RE.Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review..Expert Opin Drug Metab Toxicol2017;13:901-23 PMCID:PMC5584057

[11] Amrutkar M.Pancreatic Cancer Chemoresistance to Gemcitabine..Cancers2017;9:157 PMCID:PMC5704175

[12] Yin J,Huang X,Li T.Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy..Front Pharmacol2018;9:1697 PMCID:PMC6077182

[13] Madaan K,Verma T.Hydroxyurea: a key player in cancer chemotherapy..Expert Rev Anticancer Ther2012;12:19-29

[14] Nussbaumer S,Veuthey JL.Analysis of anticancer drugs: a review..Talanta2011;85:2265-89

[15] Henriques AC,Pedrosa J,Silva PMA.Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution..Cancer Lett2019;440-441:64-81

[16] Sun Y,Wang W,Huang SN.Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC)..DNA Repair (Amst)2020;89:102837 PMCID:PMC7188568

[17] Varela-Lopez A,Navarro-Hortal MD.An update on the mechanisms related to cell death and toxicity of doxorubicin and the protective role of nutrients..Food Chem Toxicol2019;134:110834

[18] Saleem T.Daunorubicin.2020;StatPearls [Internet]: StatPearls Publishing

[19] Wahdan-Alaswad R,Thor AD.Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: Opportunities to overcome a difficult problem..Cancer Drug Resist2020;3:1-20

[20] Rodon Ahnert J,Mok T.What it takes to improve a first-generation inhibitor to a second-or third-generation small molecule..American Society of Clinical Oncology Educational Book.2019;39:196-205

[21] Jiao Q,Ren Y,Wang Q.Advances in studies of tyrosine kinase inhibitors and their acquired resistance..Mol Cancer2018;17:36 PMCID:PMC5817861

[22] Martin-Broto J.New drugs in gastrointestinal stromal tumors..Curr Opin Oncol2020;32:314-20

[23] Han W,Qiu S.Shikonin circumvents cancer drug resistance by induction of a necroptotic death..Mol Cancer Ther2007;6:1641-9

[24] Lau MT,Parkin A.Systematic functional identification of cancer multi-drug resistance genes..Genome Biol2020;21:127 PMCID:PMC7006212

[25] Mansoori B,Davudian S,Baradaran B.The Different Mechanisms of Cancer Drug Resistance: A Brief Review..Adv Pharm Bull2017;7:339-48 PMCID:PMC5651054

[26] Housman G,Heerboth S.Drug resistance in cancer: an overview..Cancers (Basel)2014;6:1769-92 PMCID:PMC4190567

[27] Tang Y,Tong Z,Wang B.Targeted multidrug delivery system to overcome chemoresistance in breast cancer..Int J Nanomedicine2017;12:671-81 PMCID:PMC5268372

[28] Min Y,Chen S,Wang J.Combating the drug resistance of cisplatin using a platinum prodrug based delivery system..Angew Chem Int Ed Engl2012;51:6742-7

[29] Gottesman MM.Mechanisms of cancer drug resistance..Annual review of medicine.2002;53:615-27

[30] Dasari S.Cisplatin in cancer therapy: molecular mechanisms of action..Eur J Pharmacol2014;740:364-78 PMCID:PMC4146684

[31] Chen SH.New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment..Int J Mol Sci2019;20:4136 PMCID:PMC6747329

[32] Bouwman P.The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance..Nat Rev Cancer2012;12:587-98

[33] Ghosh S.Cisplatin: The first metal based anticancer drug..Bioorg Chem2019;88:102925

[34] Smith L,O’Kane SL,Lind MJ.The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays..Mol Cancer Ther2006;5:2115-20

[35] Tacar O,Dass CR.Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems..J Pharm Pharmacol2013;65:157-70

[36] Prados J,Ortiz R.Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy..Anticancer Agents Med Chem2012;12:1058-70

[37] Taymaz-Nikerel H,Eraslan S.Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells..Sci Rep2018;8:13672 PMCID:PMC6135803

[38] Huizing MT,Pieters RC,Veenhof CH.Taxanes: a new class of antitumor agents..Cancer Invest1995;13:381-404

[39] Lanni JS,Licitra EJ,Jacks T.p53-independent apoptosis induced by paclitaxel through an indirect mechanism..Proc Natl Acad Sci U S A1997;94:9679-83 PMCID:PMC23249

[40] Longley DB,Johnston PG.5-fluorouracil: mechanisms of action and clinical strategies..Nat Rev Cancer2003;3:330-8

[41] Zhang N,Xu SJ.5-Fluorouracil: mechanisms of resistance and reversal strategies..Molecules2008;13:1551-69 PMCID:PMC6244944

[42] Wang W,O’Brien V,Collie-Duguid E.Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells..Cancer Res2004;64:8167-76

[43] Ayob AZ.Cancer stem cells as key drivers of tumour progression..J Biomed Sci2018;25:20 PMCID:PMC5838954

[44] Nio K,Okada H,Hayashi T.Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma..J Hepatol2015;63:1164-72

[45] Correia AL.The tumor microenvironment is a dominant force in multidrug resistance..Drug Resist Updat2012;15:39-49 PMCID:PMC3658318

[46] Jo Y,Kim K,Choi J.Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking In Vitro Models in Anti-Cancer Drug Development..Theranostics2018;8:5259-75 PMCID:PMC6276092

[47] Lippert TH,Volm M.Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure..Arzneimittelforschung2008;58:261-4

[48] Ye Q,Shen Q,Hao J.Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids..Front Oncol2019;9:487 PMCID:PMC6581719

[49] Wang J,Shi H,Duan Z.Novel strategies to prevent the development of multidrug resistance (MDR) in cancer..Oncotarget2017;8:84559-71 PMCID:PMC5663620

[50] Wang F,Zhang Q.Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance..Biomaterials2011;32:9444-56

[51] Yuan B,Zhang Q,Zhu Y.Role of Bcl-2 on drug resistance in breast cancer polyploidy-induced spindle poisons..Oncol Lett2020;19:1701-10 PMCID:PMC7039128

[52] Mohammad RM,Lowe L,Hsu HY.Broad targeting of resistance to apoptosis in cancer..Semin Cancer Biol.2015;35 Suppl:S78-S103 PMCID:PMC4720504

[53] Lim ZF.Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy..J Hematol Oncol2019;12:134 PMCID:PMC6902404

[54] Brown R,Magnani L,Borley J.Poised epigenetic states and acquired drug resistance in cancer..Nat Rev Cancer2014;14:747-53

[55] Crystal AS,Sequist LV,Niederst MJ.Patient-derived models of acquired resistance can identify effective drug combinations for cancer..Science2014;346:1480-6 PMCID:PMC4388482

[56] Kalaydina RV,Qorri B,Szewczuk MR.Recent advances in “smart” delivery systems for extended drug release in cancer therapy..Int J Nanomedicine2018;13:4727-45 PMCID:PMC6108334

[57] Senapati S,Kumar S.Controlled drug delivery vehicles for cancer treatment and their performance..Signal Transduct Target Ther2018;3:7 PMCID:PMC5854578

[58] Li C,Wang Y,Wei G.Recent progress in drug delivery..Acta Pharm Sin B2019;9:1145-62 PMCID:PMC6900554

[59] Lonning PE.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers..Oncogene2013;32:5315-30

[60] Lovell JF,Bindner S,Fradin C.Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax..Cell2008;135:1074-84

[61] Certo M,Nishino M,Korsmeyer S.Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members..Cancer Cell2006;9:351-65

[62] Moore VDG,Certo M,Novina CD.Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737..The Journal of clinical investigation.2007;117:112-21 PMCID:PMC1716201

[63] Youle RJ.The BCL-2 protein family: opposing activities that mediate cell death..Nat Rev Mol Cell Biol2008;9:47-59

[64] Delgado Y,Milián M.Apoptosis’ activation associated to BH3 only domain and BCL-2 homology domain proteins: new way to design anti-cancer drugs..J Cancer Prev Curr Res2019;10:54-9

[65] Kastan MB,Leonard CJ.P53, cell cycle control and apoptosis: implications for cancer..Cancer Metastasis Rev1995;14:3-15

[66] Chakravarthi BV,Varambally S.Genomic and Epigenomic Alterations in Cancer..Am J Pathol2016;186:1724-35 PMCID:PMC4929396

[67] Campbell KJ.Targeting BCL-2 regulated apoptosis in cancer..Open Biol2018;8:180002 PMCID:PMC5990650

[68] Tsujimoto Y,Jaffe E.Involvement of the bcl-2 gene in human follicular lymphoma..Science1985;228:1440-3

[69] Duan H,Boxer LM.The immunoglobulin heavy-chain gene 3’ enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells..Oncogene2007;26:2635-41

[70] Thomas J,Marvel J.Bcl-X is the major pleiotropic anti-apoptotic gene activated by retroviral insertion mutagenesis in an IL-3 dependent bone marrow derived cell line..Oncogene1998;16:1399-408

[71] Rampino N,Ionov Y,Sawai H.Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype..Science1997;275:967-9

[72] Meijerink JP,Sloetjes AW,Mensink EJ.Bax mutations in cell lines derived from hematological malignancies..Leukemia1995;9:1828-32

[73] Yamamoto H,Perucho M.Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype..Cancer Res1997;57:4420-6

[74] Abrams MT,Yoon K.Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA..J Biol Chem2004;279:55809-17

[75] Callagy GM,Pinder SE,Nielsen TO.Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index..Clin Cancer Res2006;12:2468-75

[76] Bhargava V,van de Rijn M.Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity..Am J Pathol1994;145:535-40 PMCID:PMC1890342

[77] Catz SD.BCL-2 in prostate cancer: a minireview..Apoptosis2003;8:29-37

[78] Correia C,Dai H,Maurer MJ.BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma..Blood2015;125:658-67 PMCID:PMC4304111

[79] Du C,Yao M,Wang J.Bcl-2 promotes metastasis through the epithelial-to-mesenchymal transition in the BCap37 medullary breast cancer cell line..Oncol Lett2018;15:8991-898 PMCID:PMC5958888

[80] Hata AN,Faber AC.The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics..Cancer Discov2015;5:475-87 PMCID:PMC4727530

[81] Song L,Livingston S,Haura EB.Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells..Cancer Biol Ther2005;4:267-76

[82] Ikegaki N,Minna J.Expression of bcl-2 in small cell lung carcinoma cells..Cancer Res1994;54:6-8

[83] Beroukhim R,Porter D.The landscape of somatic copy-number alteration across human cancers..Nature2010;463:899-905 PMCID:PMC2826709

[84] Reed JC.Dysregulation of apoptosis in cancer..J Clin Oncol1999;17:2941-53

[85] Risnayanti C,Lee J.PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer..Sci Rep2018;8:7498 PMCID:PMC5951813

[86] Srivastava RK,Hardwick JM.Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription..J Exp Med1999;190:253-65 PMCID:PMC2195578

[87] Sui G,Yu H,Zhen B.Interleukin-17 promotes the development of cisplatin resistance in colorectal cancer..Oncol Lett2019;17:944-50 PMCID:PMC6313016

[88] Laprevotte E,du Manoir S.The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway..Oncotarget2017;8:113360-72 PMCID:PMC5768333

[89] Ng KP,Chuah CT.A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer..Nat Med2012;18:521-8

[90] O’Shaughnessy A.CHD4 in the DNA-damage response and cell cycle progression: not so NuRDy now..Biochem Soc Trans2013;41:777-82 PMCID:PMC3685327

[91] Shao S,Wang Z.CHD4/NuRD complex regulates complement gene expression and correlates with CD8 T cell infiltration in human hepatocellular carcinoma..Clin Epigenetics2020;12:31 PMCID:PMC7027061

[92] Xia L,Bellani M.CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes..Cancer Cell2017;31:653-668.e7 PMCID:PMC5587180

[93] Wang HC,Yang CC.Over-Expression of CHD4 Is an Independent Biomarker of Poor Prognosis in Patients with Rectal Cancers Receiving Concurrent Chemoradiotherapy..Int J Mol Sci2019;20:4087 PMCID:PMC6747537

[94] Hou MF,Chang TM.The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer..Exp Cell Res2017;359:458-65

[95] D’Alesio C,Gagliani MC.The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2⁺ breast cancer cells..Biol Open2019;8:bio038323 PMCID:PMC6504000

[96] Lin CY,Chang IW,Li CF.Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer..Am J Transl Res2015;7:2423-32 PMCID:PMC4697720

[97] Gasco M,Crook T.The p53 pathway in breast cancer..Breast Cancer Res2002;4:70-6 PMCID:PMC138723

[98] Han ES,Pérez VI.The in vivo gene expression signature of oxidative stress..Physiol Genomics2008;34:112-26 PMCID:PMC2532791

[99] Kurdistani SK,Reimer CL,Aaronson SA.Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage..Cancer Res1998;58:4439-44

[100] Hientz K,Bhakta-Guha D.The role of p53 in cancer drug resistance and targeted chemotherapy..Oncotarget2017;8:8921-46 PMCID:PMC5352454

[101] Zhou X,Lu H.Mutant p53 in cancer therapy-the barrier or the path..J Mol Cell Biol2019;11:293-305 PMCID:PMC6487791

[102] Wang Z,Zhu G.Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment..Dalton Trans2019;48:2536-44

[103] Bunz F,Torrance C.Disruption of p53 in human cancer cells alters the responses to therapeutic agents..J Clin Invest1999;104:263-9 PMCID:PMC408422

[104] Blandino G.New therapeutic strategies to treat human cancers expressing mutant p53 proteins..J Exp Clin Cancer Res2018;37:30 PMCID:PMC5815234

[105] Abbas T.p21 in cancer: intricate networks and multiple activities..Nat Rev Cancer2009;9:400-14 PMCID:PMC2722839

[106] Shamloo B.p21 in Cancer Research..Cancers (Basel)2019;11:1178 PMCID:PMC6721478

[107] Viale A,Orleth A.Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells..Nature2009;457:51-6

[108] Yeganeh M,Kandhi R.Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1/WAF1) in the liver..Oncogene2016;35:4200-11

[109] Piccolo MT.The dual role played by p21 may influence the apoptotic or anti-apoptotic fate in cancer..J Can Res Updates2012;1:189-202

[110] Michieli P,Lin D,Mercer WE.Induction of WAF1/CIP1 by a p53-independent pathway..Cancer Res1994;54:3391-5

[111] Gartenhaus RB,Hoffman M,Rai KR.The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine..J Mol Med (Berl)1996;74:143-7

[112] Macleod KF,Hannon G.p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage..Genes Dev1995;9:935-44

[113] Huang Y,Chen Y.The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients..J Gastroenterol2014;49:1441-52

[114] Abukhdeir AM.P21 and p27: roles in carcinogenesis and drug resistance..Expert Rev Mol Med2008;10:e19 PMCID:PMC2678956

[115] Koster R,Timmer-Bosscha H.Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer..J Clin Invest2010;120:3594-605 PMCID:PMC2947220

[116] Martinez-Rivera M.Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53..Biochem Pharmacol2012;83:1049-62 PMCID:PMC3299825

[117] Jung YS,Chen X.Examination of the expanding pathways for the regulation of p21 expression and activity..Cell Signal2010;22:1003-12 PMCID:PMC2860671

[118] Chen C,Ueda K.Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells..Cell1986;47:381-9

[119] Montazami N,Farajnia S.New insights into the mechanisms of multidrug resistance in cancers..Cell Mol Biol (Noisy-le-grand)2015;61:70-80

[120] Alfarouk KO,Taylor S.Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp..Cancer Cell Int2015;15:71 PMCID:PMC4502609

[121] Yang X,Singh A.MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer..Sci Rep2015;5:8509 PMCID:PMC4330541

[122] Nishio N,Inui K.Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells..Pharm Res2008;25:1037-42

[123] Vaidyanathan A,Gannon AL.ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells..Br J Cancer2016;115:431-41 PMCID:PMC4985349

[124] Yang Z,Bui T.A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport..J Pharmacol Exp Ther2008;327:474-81 PMCID:PMC3477805

[125] Asojo OA,Bonafé N.Structural studies of human glioma pathogenesis-related protein 1..Acta Crystallogr D Biol Crystallogr2011;67:847-55 PMCID:PMC3176621

[126] Thompson TC.Exploiting the complex biology of prostate cancer..Cancer Biol Ther2006;5:1573-6

[127] Capalbo G,Koschmieder S.Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML..Oncol Rep2013;30:2254-62

[128] Thompson TC.Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential..Yonsei Med J2010;51:479-83 PMCID:PMC2880257

[129] Li L,Yang G.GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction..Cancer Res2011;71:7694-704 PMCID:PMC3813470

[130] Gong X,Zhang D.GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin..PLoS One2017;12:e0182410 PMCID:PMC5542429

[131] Sheng X,Wang Z.GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer..Mol Cancer2016;15:25 PMCID:PMC4797332

[132] Rosenzweig T,Xiang C.Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells..Cancer Res2006;66:4139-48

[133] Gibbs GM,O’Bryan MK.The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins--roles in reproduction, cancer, and immune defense..Endocr Rev2008;29:865-97

[134] Li L,Cao G.Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling..Cancer Res2008;68:434-43

[135] Li L,Ren C.Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2..Mol Oncol2013;7:484-96 PMCID:PMC3907183

[136] Awasthi A,Lecomte FJ.Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells..Front Oncol2013;3:225 PMCID:PMC3757444

[137] Dong J,Zhang L.GLIPR1 inhibits the proliferation and induces the differentiation of cancer-initiating cells by regulating miR-16 in osteosarcoma..Oncol Rep2016;36:1585-91

[138] de Vasconcellos JF,Leal PC.SB225002 Induces Cell Death and Cell Cycle Arrest in Acute Lymphoblastic Leukemia Cells through the Activation of GLIPR1..PLoS One2015;10:e0134783 PMCID:PMC4547718

[139] Karanika S,Kurosaka S.GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells..Mol Cancer2015;14:122 PMCID:PMC4484888

[140] Sousa V,Silva M.EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study..Virchows Arch2011;458:571

[141] Iqbal N.Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications..Mol Biol Int2014;2014:852748 PMCID:PMC4170925

[142] Gutierrez C.HER2: biology, detection, and clinical implications..Arch Pathol Lab Med2011;135:55-62 PMCID:PMC3242418

[143] Slamon DJ,Jones LA.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer..Science1989;244:707-12

[144] Rexer BN.Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications..Crit Rev Oncog2012;17:1-16 PMCID:PMC3394454

[145] Hsu JL.The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer..Cancer Metastasis Rev2016;35:575-88 PMCID:PMC5215954

[146] Carpenter RL.Regulation of Apoptosis by HER2 in Breast Cancer..J Carcinog Mutagen2013;2013:003 PMCID:PMC4830426

[147] Moasser MM.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis..Oncogene2007;26:6469-87 PMCID:PMC3021475

[148] Baselga J.Novel anticancer targets: revisiting ERBB2 and discovering ERBB3..Nat Rev Cancer2009;9:463-75

[149] Castagnoli L,Tagliabue E.The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?.Cancers2019;11:902 PMCID:PMC6678616

[150] Filipits M,Gnant M.Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: a TransHERA study..Clin Cancer Res2018;24:3079-86

[151] Yang H-Y,Hung M-C.p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis..Oncogene2001;20:3695-702

[152] Ponnusamy MP,Jain M,Moniaux N.MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells..Br J Cancer2008;99:520-6 PMCID:PMC2527793

[153] Xia P,Deng Z.Cell membrane-anchored MUC4 promotes tumorigenicity in epithelial carcinomas..Oncotarget2017;8:14147-57 PMCID:PMC5355169

[154] Wolff AC,Schwartz JN.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer..Arch Pathol Lab Med2007;131:18-43

[155] Wolf-Yadlin A,Zhang Y.Effects of HER2 overexpression on cell signaling networks governing proliferation and migration..Mol Syst Biol2006;2:54 PMCID:PMC1682017

[156] Le XF,Bast RC Jr.HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways..Cell cycle2005;4:87-95

[157] Yan M,Arguello D,Gatalica Z.HER2 expression status in diverse cancers: review of results from 37,992 patients..Cancer Metastasis Rev2015;34:157-64 PMCID:PMC4368842

[158] English DP,Santin AD.HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies..Mol Diagn Ther2013;17:85-99 PMCID:PMC3660991

[159] Cooke T.What is HER2?.Eur J Oncol Nurs2000;4:2-9

[160] Ludyga N,Rosemann M.Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells..Mol Cancer Res2013;11:381-92

[161] Moey MYY,Papageorgiou CN,Hoff JT.The potential role of HER2 upregulation in metastatic breast cancer to the uterus: a case report..Clin Case Rep2016;4:928-34 PMCID:PMC5054465

[162] Gabos Z,Hanson J.Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer..J Clin Oncol2006;24:5658-63

[163] Ding W,Wang C,Ruan G.Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis..Medicine2018;97:e12908 PMCID:PMC6211907

[164] Cooke T,Lanigan A.HER2 as a prognostic and predictive marker for breast cancer..Ann Oncol.2001;12 Suppl 1:S23-8

[165] Haghnavaz N,Elieh Ali Komi D,Baradaran B.HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines..Artif Cells Nanomed Biotechnol2018;46:518-23

[166] Ferreira RB,Jahn SC.Novel agents that downregulate EGFR, HER2, and HER3 in parallel..Oncotarget2015;6:10445-59 PMCID:PMC4496366

[167] Kan S,Okamoto M.Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine..Oncol Rep2015;34:504-10

[168] Okita R,NojIma Y.Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells..Oncol Rep2015;34:2864-70 PMCID:PMC4722889

[169] Bhatnagar S.Targeting HER2 beyond breast cancer..Mol Cell Oncol2019;6:1571984 PMCID:PMC6512921

[170] Jiang N,Wang J.Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs..Exp Ther Med2018;16:2183-92 PMCID:PMC6122384

[171] Huang D,Huang H.Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition..Sci Rep2016;6:20502 PMCID:PMC4742832

[172] Pernas S.HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance..Ther Adv Med Oncol2019;11:1758835919833519 PMCID:PMC6425535

[173] Berger JC,Robinson VL,Rinker-Schaeffer CW.Metastasis suppressor genes: from gene identification to protein function and regulation..Cancer Biol Ther2005;4:805-12

[174] Melotte V,Ongenaert M.The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications..FASEB J2010;24:4153-66

[175] Kovacevic Z.The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer..Carcinogenesis2006;27:2355-66

[176] Shi XH,Chen B.The expression and localization of N-myc downstream-regulated gene 1 in human trophoblasts..PLoS One2013;8:e75473 PMCID:PMC3774633

[177] Jung EU,Lee YJ.Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells..Cancer Lett2010;298:9-15

[178] Weiler M,Pusch S.mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy..Proc Natl Acad Sci U S A2014;111:409-14 PMCID:PMC3890826

[179] Liu W,Okuda H.KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NFkappaB complex in human prostate cancer..J Biol Chem2011;286:18949-59 PMCID:PMC3099710

[180] Guan RJ,Fu Y,Shaw LM.Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer..Cancer Res2000;60:749-55

[181] Maruyama Y,Kawahara A.Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis..Cancer Res2006;66:6233-42

[182] Du A,Fan C.NDRG1 Downregulates ATF3 and Inhibits Cisplatin-Induced Cytotoxicity in Lung Cancer A549 Cells..Int J Med Sci2018;15:1502-7 PMCID:PMC6216061

[183] Albadari N,Li W.The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy..Expert Opin Drug Discov2019;14:667-82 PMCID:PMC6559821

[184] Murugesan T,Kumar S,Jegatheesan SK.Targeting HIF-2α as therapy for advanced cancers..Drug Discov Today2018;23:1444-51

[185] Jarman EJ,Turnbull AK.HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer..Breast Cancer Res2019;21:10

[186] Zhao J,Shen G,Xu B.The role of hypoxia-inducible factor-2 in digestive system cancers..Cell Death Dis2015;6:e1600 PMCID:PMC4669763

[187] Willam C,Jürgensen JS.Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells..Circ Res2000;87:370-7

[188] Tang N,Esko J.Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis..Cancer Cell2004;6:485-95

[189] Florczyk U,Stachurska A.Opposite effects of HIF-1α and HIF-2α on the regulation of IL-8 expression in endothelial cells..Free Radic Biol Med2011;51:1882-92 PMCID:PMC3202637

[190] Rini BI,Figlin RA.Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC..JCO2019;37:558-558

[191] Scully R.Role of BRCA gene dysfunction in breast and ovarian cancer predisposition..Breast Cancer Res2000;2:324-30 PMCID:PMC138653

[192] Suba Z.DNA stabilization by the upregulation of estrogen signaling in BRCA gene mutation carriers..Drug Des Devel Ther2015;9:2663-75 PMCID:PMC4440422

[193] Jasin M.Homologous repair of DNA damage and tumorigenesis: the BRCA connection..Oncogene2002;21:8981-93

[194] Murphy CG.BRCA gene structure and function in tumor suppression: a repair-centric perspective..Cancer J2010;16:39-47

[195] Godet I.BRCA1 and BRCA2 mutations and treatment strategies for breast cancer..Integr Cancer Sci Ther2017;4: PMCID:PMC5505673

[196] Ford D,Stratton M.Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium..Am J Hum Genet1998;62:676-89 PMCID:PMC1376944

[197] Guillemette S,Peng M.Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4..Genes Dev2015;29:489-94 PMCID:PMC4358401

[198] Yoshida K.Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage..Cancer Sci2004;95:866-71

[199] Reisländer T,Groelly FJ.BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors..Nat Commun2019;10:3143 PMCID:PMC6637138

[200] Zhang L,Spicer LJ.The role of tight junction proteins in ovarian follicular development and ovarian cancer..Reproduction2018;155:R183-98

[201] Rachow S,Ohnemus U.Occludin is involved in adhesion, apoptosis, differentiation and Ca2+-homeostasis of human keratinocytes: implications for tumorigenesis..PLoS One2013;8:e55116 PMCID:PMC3563667

[202] O’Driscoll MC,Urquhart JE.Recessive mutations in the gene encoding the tight junction protein occludin cause band-like calcification with simplified gyration and polymicrogyria..Am J Hum Genet2010;87:354-64 PMCID:PMC2933344

[203] Wang M,Qian X,Tang Y.Downregulation of occludin affects the proliferation, apoptosis and metastatic properties of human lung carcinoma..Oncol Rep2018;40:454-62

[204] Castro V,Luethen M.Occludin controls HIV transcription in brain pericytes via regulation of SIRT-1 activation..FASEB J2016;30:1234-46 PMCID:PMC4750406

[205] Eguchi H,Maruhashi R.Increase in resistance to anticancer drugs involves occludin in spheroid culture model of lung adenocarcinoma A549 cells..Sci Rep2018;8:15157 PMCID:PMC6181945

[206] Martin TA,Jiang WG.Loss of occludin leads to the progression of human breast cancer..Int J Mol Med2010;26:723-34

[207] Soares S,Pais A.Nanomedicine: Principles, Properties, and Regulatory Issues..Front Chem2018;6:360 PMCID:PMC6109690

[208] Morales-Cruz M,Castillo B.Smart Targeting To Improve Cancer Therapeutics..Drug Des Devel Ther2019;13:3753-72 PMCID:PMC6826196

[209] Bar-Zeev M,Assaraf YG.Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance..Drug Resist Updat2017;31:15-30

[210] Shapira A,Broxterman HJ.Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance..Drug Resist Updat2011;14:150-63

[211] Park JH,Kim J-H,Kim K.Polymeric nanomedicine for cancer therapy..Progress in Polymer Science.2008;33:1113-37

[212] Wang Z,McConville C.Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells..Nanomedicine2017;13:641-57 PMCID:PMC5364371

[213] Chang PY,Lee CY.Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells..Int J Oncol2013;43:1141-50

[214] Xiao B,Viennois E.Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles..Biomaterials2015;48:147-60 PMCID:PMC4339818

[215] Kim SS,Kim E.A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival..ACS Nano2014;8:5494-514 PMCID:PMC4076028

[216] Lin YL,Chen CH.Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies..J Nanobiotechnology2019;17:25 PMCID:PMC6364477

[217] Sawant RR,Koshkaryev A,Qureshi F.Targeted transferrin-modified polymeric micelles: enhanced efficacy in vitro and in vivo in ovarian carcinoma..Mol Pharm2014;11:375-81

[218] Zhao J,Feng SS.Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles..Biomaterials2013;34:3411-21

[219] Satpathy M,Zielinski RJ.Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using her2-targeted theranostic nanoparticles..Theranostics2019;9:778-95 PMCID:PMC6376473

[220] Mishra V,Verma A.Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems..Pharmaceutics2018;10:191 PMCID:PMC6321253

[221] Eskiler GG,Egeli U.Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer..Pharm Res2018;35:218

[222] Herceg Z.Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death..Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis2001;477:97-110

[223] Choi SH,Lee MK.Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells..Eur J Pharm Biopharm2008;68:545-54

[224] Wang X,Hou W.Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells..ACS Nano2014;8:12151-66 PMCID:PMC4334265

[225] Zhang X,Liu X.One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy..Theranostics2020;10:2918-29 PMCID:PMC7053205

[226] Lee K,Qian DZ,Liu JO.Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization..Proc Natl Acad Sci U S A2009;106:17910-5 PMCID:PMC2764905

[227] Magaye R,Bowman L.Genotoxicity and carcinogenicity of cobalt-, nickel- and copper-based nanoparticles..Exp Ther Med2012;4:551-61 PMCID:PMC3501377

[228] Pietruska JR,Smith A.Bioavailability, intracellular mobilization of nickel, and HIF-1α activation in human lung epithelial cells exposed to metallic nickel and nickel oxide nanoparticles..Toxicol Sci2011;124:138-48 PMCID:PMC3196652

[229] Zhao Y,Zhang PF.Differential Regulation of Gene and Protein Expression by Zinc Oxide Nanoparticles in Hen’s Ovarian Granulosa Cells: Specific Roles of Nanoparticles..PLoS One2015;10:e0140499 PMCID:PMC4604165

[230] Yang T,Cao F,Liu B.Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis..Int J Nanomedicine2016;11:6679-92 PMCID:PMC5154724

[231] Satapathy SR,Preet R.Silver-based nanoparticles induce apoptosis in human colon cancer cells mediated through p53..Nanomedicine (Lond)2013;8:1307-22

[232] Disdier C,Cosnefroy A.Tissue biodistribution of intravenously administrated titanium dioxide nanoparticles revealed blood-brain barrier clearance and brain inflammation in rat..Part Fibre Toxicol2015;12:27 PMCID:PMC4559366